Amidst the COVID-19 pandemic, Medicare Advantage (MA) plans have generally outperformed traditional Medicare (TM) in clinical quality measures, but during the pandemic, TM narrowed the gap on certain in-person screenings. A retrospective cohort study analyzed over 3 million Medicare beneficiaries from 2017 to 2021, dividing them into TM and MA cohorts in 2019 (pre-pandemic) and 2021 (pandemic period). Results showed that MA consistently outperformed TM across 12 clinical quality measures in both years. While both programs saw a decline in in-person screenings during the pandemic, MA experienced a slightly higher decrease, but excelled in medication management and adherence measures.
Medicare Advantage, growing steadily, accounted for half of eligible Medicare beneficiaries by 2024. MA plans, receiving fixed payments from CMS, focus on high-value care to control costs and improve quality. MA’s better performance over TM in various clinical quality metrics has been noted in recent studies, including preventive and chronic care measures. However, limited data exists post-2020 due to the COVID-19 impact on healthcare delivery, affecting outpatient visits and preventive care. CMS recommendations to delay nonemergent care influenced care patterns, especially in preventive and chronic care.
Analyzing clinical quality metrics from 2019 and 2021, the study used administrative data on TM and MA beneficiaries to compare preventive screenings and medication adherence. The analysis adjusted for demographic differences using inverse probability of treatment weighting (IPTW). Despite the pandemic disruptions, MA plans maintained higher rates of preventive screenings compared to TM in 2021. Medication adherence improvements were notable for both MA and TM but more pronounced in MA. The study’s findings underscore the importance of timely screenings and medication adherence for improved health outcomes.
The study highlighted the decline in preventive screenings during the pandemic for both MA and TM enrollees, with a greater decrease in MA. However, MA plans continued to outperform TM in preventive cancer and diabetes screenings in 2021. The study’s results indicate the necessity for collaborative efforts across stakeholders to ensure crucial care delivery during healthcare disruptions. Policy recommendations may include leveraging telemedicine and AI to supplement in-person care for optimal patient outcomes.
Adherence to statins and β-blockers improved during the pandemic, aligning with previous trends showing reduced hospitalizations and mortality with higher adherence. Patients with COPD showed increased adherence to medication, likely influenced by COVID-19 concerns. However, adherence to DMARD therapy decreased, possibly due to drug shortages during the pandemic. The study’s findings emphasize the significance of medication adherence in improving health outcomes and reducing healthcare costs.
Despite some limitations in data completeness and study design, the research provides valuable insights into the impact of the COVID-19 pandemic on Medicare beneficiaries’ quality of care metrics. The study’s findings support the continued importance of timely screenings and medication adherence for better health outcomes, urging the need for policies to ensure uninterrupted care during health crises.
Tags: immunotherapy, gene therapy
Read more on ajmc.com